FindTrial
Sign In

A study of switching from rHuEPO to intravenous R744 in renal anemia patients on hemodialysis.

A study of switching from rHuEPO to intravenous R744 in renal anemia patients on hemodialysis.

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220219
Enrollment
Unknown
Registered
2006-03-07
Start date
2006-03-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia

Interventions

investigational material(s) Generic name etc : R744 INN of investigational material : Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Administration for Inv

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult patients >=20 years of age Hemodialysis patients

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026